- Home
- BRT vs IVVD Comparison
BRT vs IVVD Comparison
Compare BRT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | IVVD |
|---|---|---|
| Founded | 1972 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.0M | 212.6M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRT | IVVD |
|---|---|---|
| Price | $13.11 | $0.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.50 | $10.00 |
| AVG Volume (30 Days) | 51.5K | ★ 3.6M |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | $53,426,000.00 |
| Revenue This Year | $1.10 | $12.40 |
| Revenue Next Year | $7.98 | $44.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.46 | ★ 110.47 |
| 52 Week Low | $12.51 | $0.53 |
| 52 Week High | $15.63 | $3.07 |
Technical Indicators
Market Signals| Indicator | BRT | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 42.30 |
| Support Level | N/A | $0.53 |
| Resistance Level | $14.99 | $1.02 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.82 | 34.49 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About IVVD Invivyd Inc.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.